University Medical Center Hamburg-Eppendorf — Sponsor Intelligence | 11 EU Trials

Filter these 11 trials by condition, phase, country and more.

Open in Search →

11 Registered trials

4 Recruiting

6 Completed trials

10 Countries active

31 Unique IMPs

100% Results reported

Phase III

Phase II/III

Phase II

Phase III: 3 Phase II/III: 2 Phase II: 2 Phase I/II: 1 Phase III/IV: 1 Phase IV: 1 Phase I: 1

Oversight events:

2 temporary halts across 1 trial

View oversight register →

100%

6 of 6 completed trials have published summary results (EU CTR Article 37 — 12-month obligation).

View full Transparency Scoreboard →

Top indications

Cholangiocarcinoma 1 Chronic hepatitis B 1

Top IMPs

CARFILZOMIB 2 ISATUXIMAB 2 LENALIDOMIDE 2 BORTEZOMIB 1 DARATUMUMAB 1 DEXAMETHASONE 1 DEXAMETHASONE DIHYDROGEN PHOSPHATE DISODIUM PH. EUR. 1 ELOTUZUMAB 1 ESOMEPRAZOLE MAGNESIUM TRIHYDRATE 1 IXAZOMIB CITRATE 1 MEBENDAZOLE 1 PLACEBO 1

All trials

11 total

SIOP PNET 5 medulloblastoma Pending

2024-513724-42-00 Phase II/III 10 countries
Early treatment of irregular heartbeat (atrial fibrillation) to prevent a recurrent stroke Recruiting

2025-521260-35-00 Phase IV 3 countries
Thrombolysis with Tenecteplase for Acute Ischemic Stroke in Patients taking Direct Oral Anticoagulants Recruiting

2025-521762-99-00 Phase III 1 country TENECTEPLASE
Combination treatment of Belantamab Mafodotin and Venetoclax in treatment of relapsed and refractory t(11;14) Multiple Myeloma (Phase I/IIa)… Recruiting

2024-511794-30-00 Phase I/II 1 country
Stop of proton-pump inhibitor treatment in patients with liver cirrhosis – a doubleblind, placebo-controlled trial (STOPPIT) Recruiting

2023-509863-26-00 Phase III/IV 1 country ESOMEPRAZOLE MAGNESIUM TRIHYDRATE; PLACEBO
A Clinical Phase II, multicenter, Open-label study evaluating iNduction, consolidation and maintenance treatment with Isatuximab (SAR650984)… Ended

2024-511791-32-00 Phase II 1 country CARFILZOMIB; ISATUXIMAB; LENALIDOMIDE
TherVacB_Phase1a: Open phase 1a trial to assess the safety and immunogenicity of a heterologous protein prime/MVA boost therapeutic hepatiti… Ended

2024-514231-26-00 Phase I 1 country
Adjuvant chemotherapy with gemcitabine and cisplatin compared to standard of care after curative intent resection of cholangiocarcinoma and … Ended

2024-517340-61-00 Phase III 4 countries
Allogeneic stem cell transplantation vs. conventional therapy as salvage therapy for relapsed / progressed patients with multiple myeloma af… Ended

2024-510590-14-00 Phase III 1 country BORTEZOMIB; CARFILZOMIB; DARATUMUMAB; DEXAMETHASONE; DEXAMETHASONE DIHYDROGEN PH…
Durability of Immunity induced by the Ebolavirus Vaccine VSV-EBOV and Assessment of a Booster Dose for Pre-Exposure Prophylaxis in Individua… Ended

2024-517352-35-00 Phase II/III 1 country RECOMBINANT VESICULAR STOMATITIS VIRUS - ZAIRE EBOLAVIRUS VACCINE (LIVE)
A study to evaluate the safety and efficacy of mebendazole in combination with low-dose Ara-C in elderly patients with relapsed/refractory a… Ended

2024-518363-36-00 Phase II 1 country MEBENDAZOLE

Showing 1–11 of 11 trials

← All sponsors A–Z